drugset / Trial / NCT00994253
Evaluating the Effect of Aliskiren Versus HCTZ on Coronary Flow Reserve in Hypertensive Type II Diabetics
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the effect of Tekturna (aliskiren), in combination with an ACE and calcium channel blocker in hypertensive patients diagnosed with Type II diabetes.
Timeline
- Start
- 2009-08
- Primary completion
- 2012-12
- Completion
- 2012-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aliskiren | Small molecule | 300 mg | Oral |
| Comparator | Hydrochlorothiazide | Unknown | 25 mg | Oral |